Impact of selexipag use within 12  months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study

ConclusionSelexipag initiation within 12  months of PAH diagnosis demonstrated reductions in all-cause hospitalization rate and medical costs.

Source: The Clinical Respiratory Journal - October 8, 2023 Category: Respiratory Medicine Authors: Yuen Tsang, Michael Stokes, Yong ‐Jin Kim, Rong Tilney, Sumeet Panjabi Tags: ORIGINAL ARTICLE Source Type: research